Tocilizumab

Tocilizumab is a humanised monoclonal antibody and a biologic medicine classified as an interleukin-6 (IL-6) receptor antagonist. Interleukin-6 is a signalling protein involved in inflammation, immune responses, and the development of several inflammatory and autoimmune disorders. Tocilizumab binds to soluble and membrane-bound IL-6 receptors, preventing IL-6 from activating its usual signalling pathways and thereby reducing inflammation. It is used in selected patients with conditions such as rheumatoid arthritis, giant cell arteritis, juvenile idiopathic arthritis, and systemic sclerosis-associated interstitial lung disease. In certain settings, it is also used to manage severe cytokine release syndrome associated with cancer immunotherapy and COVID-19 in hospitalised patients who meet specific treatment criteria. Depending on the indication and formulation, tocilizumab can be administered by intravenous infusion or subcutaneous injection. It may be used alone or alongside other medicines, including conventional disease-modifying antirheumatic drugs, when appropriate. By suppressing IL-6 signalling, treatment can improve disease control, but it also affects immune function and may increase susceptibility to serious infections. Appropriate patient selection, screening for latent infections, laboratory testing, and ongoing clinical monitoring are therefore essential. The dose, route, frequency, and duration depend on the condition being treated, the patient's age and weight, response to therapy, and the applicable product information.

Tocilizumab was developed as a humanised monoclonal antibody targeting the interleukin-6 receptor, based on research identifying IL-6 as an important mediator of inflammation and immune-system activity. Clinical development evaluated its effectiveness in rheumatoid arthritis and other inflammatory conditions, including juvenile idiopathic arthritis and giant cell arteritis. The European Commission granted marketing authorisation for RoActemra on January 16, 2009, and the United States Food and Drug Administration (FDA) initially approved tocilizumab in January 2010 for rheumatoid arthritis. Subsequent approvals expanded its use to additional inflammatory diseases and specific acute inflammatory complications. Tocilizumab has also been authorised for selected patients with severe or life-threatening cytokine release syndrome associated with CAR T-cell therapy and for certain hospitalised patients with COVID-19. The international clinical development programme included trials evaluating joint disease activity, physical function, structural joint damage, and other disease-specific outcomes. Regulatory indications and approved formulations vary by jurisdiction and product, so the relevant local prescribing information should be consulted before treatment.

Tocilizumab is used to treat several inflammatory and immune-mediated conditions. Approved indications in the United States include moderately to severely active rheumatoid arthritis in adults who have responded inadequately to one or more disease-modifying antirheumatic drugs, giant cell arteritis in adults, and slowing the decline in pulmonary function in adults with systemic sclerosis-associated interstitial lung disease. It is also indicated for active polyarticular and systemic juvenile idiopathic arthritis in eligible children aged two years and older. Additional authorised uses include severe or life-threatening CAR T-cell-induced cytokine release syndrome and selected hospitalised adults with COVID-19 who require supplemental oxygen or respiratory support and receive systemic corticosteroids. In rheumatoid arthritis and certain juvenile arthritis conditions, tocilizumab may be used alone or with other medicines, such as methotrexate, depending on the indication and clinical circumstances. Treatment should be selected according to the confirmed diagnosis, disease severity, age, previous therapy, and the applicable regulatory approval.

Tocilizumab is administered either by intravenous infusion or subcutaneous injection, depending on the condition, formulation, patient age, body weight, and local prescribing guidance. For adult rheumatoid arthritis, intravenous treatment is commonly administered every four weeks, with the dose determined by body weight and the applicable product label; subcutaneous treatment is generally administered weekly or every other week according to the prescribed regimen. Giant cell arteritis and systemic sclerosis-associated interstitial lung disease have indication-specific dosing schedules. Paediatric dosing for juvenile idiopathic arthritis is based on body weight and may differ according to the disease and route of administration. For cytokine release syndrome and COVID-19, intravenous dosing is based on clinical criteria and body weight, with repeat dosing permitted only under specified conditions. Treatment duration depends on disease control, response, tolerability, and the need for ongoing therapy. Intravenous administration should be performed by trained healthcare professionals, while subcutaneous injections should follow the prescribed product instructions. Doses may need to be withheld, adjusted, or discontinued because of infections or laboratory abnormalities.

Common adverse effects of tocilizumab include upper respiratory tract infections, headache, high blood pressure, injection-site reactions, and changes in liver enzymes or blood cell counts. Patients may also experience nausea, abdominal discomfort, or increased cholesterol and triglyceride levels. Infusion-related reactions can occur during or after intravenous administration, while redness, itching, or discomfort may occur at the injection site. The type and severity of side effects vary according to the indication, dose, route of administration, and individual health factors. Regular clinical assessment and laboratory monitoring help identify treatment-related abnormalities. Patients should report persistent fever, new symptoms of infection, unusual bruising, or other concerning changes to their healthcare professional rather than adjusting treatment independently.

Tocilizumab carries an important warning for serious infections, including tuberculosis, bacterial infections, invasive fungal infections, and other opportunistic infections that may require hospitalisation or can be life-threatening. Treatment should not be initiated during an active serious infection and should be interrupted if a serious infection develops until it is adequately controlled. Other important risks include liver injury, severe neutropenia, thrombocytopenia, and gastrointestinal perforation, particularly in patients with diverticulitis or other relevant intestinal conditions. Severe hypersensitivity and infusion reactions can also occur. Tocilizumab may reduce signs of inflammation, including C-reactive protein levels, which can make some infections less apparent. Patients should be assessed promptly if they develop persistent abdominal pain, fever, jaundice, or other symptoms suggesting a serious complication. Depending on the nature and severity of the adverse event, clinicians may withhold treatment, modify the dose, or permanently discontinue therapy in accordance with the applicable prescribing information.

Before starting tocilizumab, clinicians should assess for active and latent tuberculosis, review infection history, and obtain baseline blood counts and liver function tests. Lipid levels should also be assessed because treatment may increase cholesterol and triglycerides. Ongoing monitoring generally includes neutrophil and platelet counts, liver enzymes, lipid levels, and clinical assessment for infection. Live vaccines should generally be avoided during treatment, and vaccination status should be reviewed before therapy when possible. Tocilizumab requires particular caution in patients with recurrent infections, chronic liver disease, low blood cell counts, or a history of diverticulitis. Pregnancy and breastfeeding require individual assessment of potential benefits and risks using the applicable product information. By suppressing IL-6 signalling, tocilizumab can alter the activity of certain drug-metabolising enzymes and may change exposure to some medicines, including selected narrow-therapeutic-index drugs. Clinicians and pharmacists should review prescription medicines, over-the-counter products, and supplements before treatment and when tocilizumab is started or stopped.

Confirm the treatment indication, disease activity, prior therapies, and appropriate administration route before initiating tocilizumab. Complete baseline screening for tuberculosis and other relevant infections, obtain a full blood count and liver function tests, and assess lipid levels. Review vaccination history and arrange appropriate non-live vaccinations before treatment where feasible. Explain that serious infections may occur even when typical inflammatory markers are low, and advise patients to report infection symptoms promptly. For intravenous treatment, follow the product-specific preparation, dilution, infusion, and observation instructions. For subcutaneous treatment, provide training on injection technique, storage, handling, and disposal. Schedule follow-up laboratory testing according to the product label and the patient's risk factors, and review concomitant medicines for interactions caused by changes in drug-metabolising enzyme activity. Assess for gastrointestinal symptoms, liver injury, and infusion reactions throughout treatment. Coordinate care among the prescribing specialist, pharmacist, laboratory team, and other clinicians to support safe administration and appropriate treatment modification.